Finnish Bioindustries FIB - Suomen Bioteollisuus ry

🚀 We are growing and #hiring: Head of Investor Relations at Innovestor We are looking for a dynamic and experienced professional to join our management team as the Head of Investor Relations. The overarching goal of this role is to drive the company’s capital-raising efforts and develop investor relationships while leading a team of skilled IR professionals.  Reporting directly to the CEO, the Head of Investor Relations will play a pivotal role in shaping Innovestor’s growth agenda and strategic direction for the future. Discover more about this exciting leadership opportunity and how to apply at this link 👉 https://lnkd.in/dtCAs7ET #InvestorRelations #FinanceCareers #Leadership #InnovestorCareers

Member introduction💡 #Precisionmedicine offers hope for rare cancers Sartar Therapeutics is developing SAR003, an innovative drug targeting rare soft tissue cancers like GIST. This groundbreaking therapy precisely attacks #cancer cells and offers a solution for patients resistant to existing treatments. Learn more about how Finnish biotech is paving the way for advanced cancer therapies: https://lnkd.in/dTj9-AcY #cancertreatment #biotechnology Finnish Bioindustries FIB - Suomen Bioteollisuus ry

Jäsenesittely💡Täsmälääkkeet tuovat toivoa harvinaisiin syöpiin: Suomalainen Sartar Therapeutics kehittää innovatiivista SAR003-lääkettä harvinaisiin pehmytkudossyöpiin, kuten GIST-kasvaimiin. Uusi lääke kohdistuu tarkasti syöpäsoluihin ja tarjoaa ratkaisun myös niille potilaille, joilla aiemmat hoidot eivät enää tehoa. 👉 Lue lisää ja tutustu, miten suomalainen biotekniikka tuo uusia mahdollisuuksia syöpähoitoon: https://lnkd.in/dTv7Y8bY #täsmälääketiede #syöpä #syöpähoito #bioteknologia Finnish Bioindustries FIB - Suomen Bioteollisuus ry

Tieteellinen asiantuntijamme (Senior Scientific Advisor) Markus Perola on valittu Duodecimin hallituksen uudeksi puheenjohtajaksi Duodecimin valtuuskunnan toimesta. Uudessa hallituksen puheenjohtajan roolissaan Markus rohkaisee yhdessä rakentamaan eteenpäin yhteisöä, joka ei ainoastaan ylläpidä, vaan uudistaa suomalaisen lääketieteen ja terveyden edistämistä. Lämpimät onnittelumme! https://lnkd.in/dc2s9wC9

We are currently looking for a Senior Bioprocess Engineer. For more information: https://lnkd.in/dsXMFdsS

Great news! Memorial Hospitals Group in Turkey has selected Aiforia as a partner for AI-assisted pathology image analysis in clinical diagnostics. “We are proud to be the first pathology lab in Turkey with full digital workflow and fully digitized for biopsies. Next step was to include clinical AI use, and now we are happy to reach this level with Aiforia. We will use Aiforia’s AI models for prostate, breast and lung carcinoma patients and they will assist us in our diagnostic path. We are happy that we can offer the most innovative and comprehensive diagnostic tools to our patients. We will expand our scope and tools with further collaborations in other disease groups in future,” says Dr. İlknur Turkmen, Director of Pathology at Memorial Healthcare Group. Read more: https://hubs.la/Q02ZYdGc0

Circio is teaming up with the LNP-experts at Certest for delivery of our circVec-DNA gene therapy format to specific tissues. circVec-DNA has already demonstrated remarkable >6 months durability on a single dose and uo to 15x improvement vs. standard mRNA-based vector systems in muscle tissue. The Certest collaboration will enable us to extend these promising results to other tissues to identify target diseases for development of novel circVec therapeutic candidates.

𝐒𝐭𝐞𝐚𝐭𝐨𝐬𝐢𝐬 𝐚𝐧𝐝 𝐩𝐡𝐨𝐬𝐩𝐡𝐨𝐥𝐢𝐩𝐢𝐝𝐨𝐬𝐢𝐬 𝐬𝐜𝐫𝐞𝐞𝐧𝐢𝐧𝐠 𝐰𝐢𝐭𝐡 𝐡𝐢𝐠𝐡-𝐜𝐨𝐧𝐭𝐞𝐧𝐭 𝐢𝐦𝐚𝐠𝐢𝐧𝐠 As a specialized and skilled ADME-tox service provider, we offer a broad range of research services. Our recently launched drug-induced liver injury (DILI) service package, part of our in vitro toxicology offerings, is designed to evaluate potential hepatotoxicity risks of drug candidates early on. Steatosis, characterized by fatty acid and lipid accumulation, and phospholipidosis, indicative of lysosomal dysfunction, can emerge at lower drug concentrations than cell necrosis, amplifying the risk of hepatotoxicity. Steatosis and phospholipidosis assay is one of the assays included in our DILIscope service package. Visit our website to learn more about our DILIscope service package and let us help you with derisking your compounds! Click the link in the comments to get started! Admescope a Symeres company #Admescope #Symeres #druginducedliverinjury #hepatotoxicity #invitrotoxicology

At Blueprint Genetics, we don't just deliver results, we provide expert clinical interpretation services. Our team of world-class geneticists uses our advanced platform to analyze up to 5 million genetic variants. With deep and uniform sequencing coverage, validated with thousands of rare disease patients, trust us to provide accurate insights every time. Discover how we can pinpoint what matters for each patient at www.blueprintgenetics.com. 

Join our next webinar with Vincenzo L'Imperio L’Imperio, Pathologist and Assistant Professor, and Darshan Kumar, Director of Global FAS team, to discover how artificial intelligence (AI) can be beneficial in renal pathology. Dr. L’Imperio will discuss how their research team developed a fully automated AI-based tool, named “Galileo”, for assisting pathologists in the evaluation of renal biopsies in the kidney transplant setting. 🗓️ Monday, December 16 🕓 10:00-11:00 a.m. EST / 4:00-5:00 p.m. CET ➡️ Register here (note that you can register even if you cannot attend the live session; we will send you a recording after the webinar): https://hubs.la/Q02Zwblw0 #webinar #pathology #renalpathology #kidneytransplant #artificialintelligence #AI